In April, biopharma transactions amounted to $12.8 billion, a sharp decline from March’s $29.48 billion. However, with $79.66 billion in deal value during the first four months of 2025, the sector has ...

The U.S. FDA’s decision to phase out animal testing for INDs is driving a new market of alternative, nonanimal testing technologies like organoids and organs-on-a-chip, speakers at Bio Korea 2025 said ...

As biopharma companies continue to roll out their first-quarter  earnings, Trump administration tariffs remain at the top of investors’ minds. While executives offer their various strategies to ...

The U.S. FDA typically announces its inspections at facilities located outside the U.S. – a courtesy not extended to domestic manufacturing sites. This is about to change per an agency press release ...

UTR Therapeutics Inc. has submitted an IND application to the FDA for UTRxM1-18, a novel therapeutic approach for targeting c-MYC-driven cancers. Pending approval, a first-in-human phase I trial is ...

Individuals with autoimmune diseases affecting the thyroid can suffer eye complications in the form of Graves’ orbitopathy, in which inflammation in and around the orbit leads to eyelid retraction, ...

Ahead Therapeutics SL has received positive feedback from the EMA on its way toward initiating regulatory toxicology studies for its lead program in myasthenia gravis. The feedback supports the ...

Approximately 90% of all kidney cancers involve renal cell carcinoma, against which researchers are racing to find more effective therapies. One of the major challenges in treating this and other ...

Individuals with cystic fibrosis show a notably higher rate of attention deficit hyperactivity disorder (ADHD) symptoms than the general population. This association points to a possible role of the ...

Neuboron Medtech Research Institute Ltd. has disclosed boron-containing lipoic acid derivatives and vesicle forms acting as boron neutron capture therapy (BNCT) agents reported to be useful for the ...

Teijin Pharma Ltd. has identified crystalline forms of oxazepine derivatives acting as orexin OX2 receptor agonists reported to be useful for the treatment of narcolepsy, hypersomnia and sleep apnea.

Co. Ltd. has divulged proteolysis targeting chimera (PROTAC) compounds comprising an E3 ubiquitin ligase binding moiety covalently linked to a tyrosine-protein phosphatase non-receptor type 2 (PTPN2; ...